These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25196083)

  • 1. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
    Brygger L; Herrstedt J;
    Expert Opin Drug Saf; 2014 Oct; 13(10):1407-22. PubMed ID: 25196083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
    Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
    Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
    Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Mori-Vogt S; Blazer M
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
    Lin SJ; Hatoum HT; Buchner D; Cox D; Balu S
    BMC Health Serv Res; 2012 Jul; 12():215. PubMed ID: 22823909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
    Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
    J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
    Fabi A; Malaguti P
    Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006272. PubMed ID: 24323437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.